Tip II topoizomeraza — разлика између измена

'''Tip II [[topoizomeraza|topoizomeraze]]''' presecaju oba lanca DNK heliksa simultano radi upravljanja zamršenjem DNK i supernamotavanjima.<ref name="pmid11395412">{{cite journal | author = Champoux JJ | title = DNA topoisomerases: structure, function, and mechanism | journal = Annu. Rev. Biochem. | volume = 70 | issue = | pages=369-413 | year = 2001 | pmid = 11395412 | doi = 10.1146/annurev.biochem.70.1.369 | url = | issn = }}</ref><ref name="urlNational Academy of Sciences: NAS Award in Molecular Biology">{{cite web | url = http://www.nasonline.org/site/PageServer?pagename=AWARDS_molbio | title = National Academy of Sciences: NAS Award in Molecular Biology | author = | authorlink = | coauthors = | date = | format = | work = | publisher = National Academy of Science | pages = | language = | archiveurl = | archivedate = | quote = | accessdate = 7. 1. 2009. }}</ref> One koriste hidrolizu [[Adenozin trifosfat|ATP-a]], za razliku od tip I [[topoizomeraza]]. U tom procesu, ovi enzimi menjanju [[koeficijent povezivanja]] cirkularne DNK za +/-2.

Eksperimentalni antitumorski lek -{[[m-AMSA]]}- (4'-(9'-akridinilamino)metanesulfon-m-anizidid) takođe inhibira tip 2 topoizomerazu.<ref name="pmid15010369">{{cite journal |authorauthor1=Willmore E, |author2=de Caux S, |author3=Sunter NJ, |author4=''et al.'' |title=A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia |journal=Blood |volume=103 |issue=12 |pages=4659-65 |year=2004 |pmid=15010369 |doi=10.1182/blood-2003-07-2527}}</ref>